Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluating Pharmacological Treatments for Excessive Daytime Sleepiness in Obstructive Sleep Apnea: A Comprehensive Network Meta-Analysis and Systematic Review Publisher Pubmed



Neshat SS1, 2 ; Heidari A3 ; Henriquezbeltran M4 ; Patel K2 ; Colaco B2 ; Arunthari V2 ; Lee Mateus AY2 ; Cheung J2 ; Labarca G5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Epidemiology and Statistics, University of California, San Francisco, CA, United States
  2. 2. Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic Jacksonville, FL, United States
  3. 3. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Nucleo de Investigacion en Ciencias de la Salud, Universidad Adventista de Chile, Chillan, Chile
  5. 5. Division of Pulmonary and Critical Care Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States
  6. 6. Department of Respiratory Diseases, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

Source: Sleep Medicine Reviews Published:2024


Abstract

Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS). Pharmacotherapy offers a potential treatment approach for EDS in OSA patients. This systematic review and meta-analysis aimed to assess the efficacy and safety of pharmacological interventions for alleviating EDS in patients with OSA. Following PRISMA guidelines, we included randomized controlled trials investigating pharmacological treatments for EDS in adult OSA until August 2023. We conducted meta-analysis, subgroup, and meta-regression analyses using a random effects model. Finally, a network meta-analysis synthesized direct and indirect evidence, followed by a comprehensive safety analysis. We included 32 articles in the meta-analysis (n = 3357). Pharmacotherapy showed a significant improvement in the Epworth Sleepiness Scale (ESS) score (Mean Difference (MD) −2.73, (95 % Confidence Interval (CI) [−3.25, −2.20], p < 0.01) and Maintenance of Wakefulness Test (MWT) score (MD 6.00 (95 % CI [2.66, 9.33] p < 0.01). Solriamfetol, followed by Pitolisant and modafinil, exhibited the greatest ESS reduction, while Danavorexton, followed by Solriamfetol and MK-7288, had the strongest impact on MWT. MK-7288 had the most total adverse events (AEs), followed by Danavorexton and armodafinil. Pharmacological Interventions significantly alleviate EDS in OSA patients but with heterogeneity across medications. Treatment decisions should involve a personalized assessment of patient factors and desired outcomes. © 2024 Elsevier Ltd
Experts (# of related papers)
Other Related Docs
25. Mild Traumatic Brain Injury: Insomnia or Sleepiness, Interdisciplinary Neurosurgery: Advanced Techniques and Case Management (2023)
47. Sleep Apnea Symptoms in Diabetics and Their First Degree Relatives, International Journal of Preventive Medicine (2012)